Citius Oncology, Inc.

Name: Citius Oncology, Inc. standardized financial statements, quarterly
Creator: Listed

CTORNasdaqCIK 1851484HealthcareFiscal year ends Sep 30

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.5m, Q3 FY2026

Operating income−$8.7m, Q3 FY2026

Net income−$8.9m, Q3 FY2026

Citius Oncology, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q4 FY20242024-09-30	Q1 FY20252024-12-31	Q2 FY20252025-03-31	Q3 FY20252025-06-30	Q4 FY20252025-09-30	Q1 FY20262025-12-31	Q2 FY20262026-03-31	Q3 FY20262026-06-30
Revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	3.9	1.7	1.5
Cost of revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	0.8	0.3	0.5
Gross profit	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	3.2	1.3	1.0
Research and development	$m	not reported	1.1	1.3	1.1	1.3	1.3	3.1	0.9	1.1	1.0	1.1	0.2
Operating income	$m	(0.4)	(0.2)	(0.3)	(4.6)	(6.7)	(6.4)	(7.5)	(4.9)	(4.7)	(5.3)	(28.6)	(8.7)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	0.2	0.1	0.0	0.0	0.2
Income tax	$m	not reported	0.1	0.1	0.1	0.1	0.3	0.3	0.3	0.3	0.3	(0.2)	(0.1)
Net income	$m	0.2	(4.7)	(4.8)	(4.8)	(6.8)	(6.7)	(7.7)	(5.4)	(5.0)	(5.5)	(26.6)	(8.9)
Diluted EPS	$ per share	0.02	(0.07)	(0.07)	(0.07)	not reported	(0.09)	(0.11)	(0.08)	not reported	(0.06)	(0.27)	(0.08)
Basic EPS	$ per share	0.02	(0.07)	(0.07)	(0.07)	not reported	(0.09)	(0.11)	(0.08)	not reported	(0.06)	(0.27)	(0.08)

Balance sheet

Cash and equivalents$16.6m, Q3 FY2026

Shareholders' equity$40.4m, Q3 FY2026

Citius Oncology, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	FY20242024-09-30	Q1 FY20252024-12-31	Q2 FY20252025-03-31	Q3 FY20252025-06-30	FY20252025-09-30	Q1 FY20262025-12-31	Q2 FY20262026-03-31	Q3 FY20262026-06-30
Cash and equivalents	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	7.3	2.6	16.6
Current assets	$m	7.7	0.1	0.1	0.0	11.0	17.1	18.0	18.3	27.5	37.1	29.4	42.7
Total assets	$m	47.7	72.6	48.7	49.2	84.4	90.5	91.4	91.7	101	110	101	112
Current liabilities	$m	21.0	2.0	2.8	3.1	32.7	43.4	49.7	53.0	49.5	44.7	58.8	58.8
Total liabilities	$m	22.2	not reported	not reported	not reported	38.2	49.2	55.8	59.3	56.1	51.6	65.4	71.7
Shareholders' equity	$m	25.5	22.7	19.8	17.0	46.1	41.3	35.6	32.4	44.9	58.4	35.3	40.4

Cash flow

Operating cash flow−$2.7m, Q3 FY2026

Citius Oncology, Inc., cash flow, quarterly
Line item	Unit	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q1 FY20262025-12-31	Q2 FY20262026-03-31	Q3 FY20262026-06-30
Operating cash flow	$k	(169)	(100)	(113)	(219)	(192)	(366)	(7,355)	(3,832)	(2,711)

Diluted shares (weighted)107.89m, Q3 FY2026

Citius Oncology, Inc., shares, quarterly
Line item	Unit	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q1 FY20252024-12-31	Q2 FY20252025-03-31	Q3 FY20252025-06-30	Q1 FY20262025-12-31	Q2 FY20262026-03-31	Q3 FY20262026-06-30
Diluted shares (weighted)	m shares	6.6	6.6	6.6	67.5	67.5	67.5	71.6	71.6	71.6	87.5	100	108

Shares outstanding: 92.98m at Aug 13, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.